Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerClinical validity and utility of genetic risk scores in prostate cancerPopulation-based screening for cancer: hope and hype.Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Personalized prostate cancer care: from screening to treatment.Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.Clinically Meaningful Use of Blood Tumor Markers in Oncology.Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.E-Science technologies in a workflow for personalized medicine using cancer screening as a case study.Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mLRole of mpMRI of the prostate in screening for prostate cancer.Variability of cancer risk within an area: time to complement the incidence rate.A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.What's new in screening in 2015?Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.Genetic predisposition to prostate cancer.Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions.Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study.Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples.Update on Screening for Urological Malignancies.Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer.Genetic risk scores and family history as predictors of schizophrenia in Nordic registers.Summary statement on screening for prostate cancer in Europe.Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7.Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data.The genetic classification of prostate cancer: what's on the horizon?Effects of pre-notification, invitation length, questionnaire length and reminder on participation rate: a quasi-randomised controlled trial.A review of prostate cancer genome wide association studies (GWAS).
P2860
Q26738703-CD581CDC-58A2-4553-9796-9070C602DA74Q26746219-7232489E-4295-4473-A17B-3C1DD0AA15A5Q30251601-42B6D4FB-1124-4EAD-9593-B05CB7E98CFDQ33822218-3B0ED897-2D13-4623-8E53-DDC74BBF3798Q36157852-F54F580F-84C6-45A1-950D-198CB9D34634Q36356727-AD5270E7-A10F-4F7C-B966-AA2CDE3396CEQ37113160-65426612-D461-4635-A46A-AB6B91FFFA6FQ37113165-DB84CD56-7B3F-4BDB-B07D-3DE1AFBAB21DQ37500722-C6211F54-C387-4334-9006-F83D84D548E1Q37706084-F073078A-07A9-4E9F-987F-ED42E7696EEFQ38371172-35CA0A92-3716-4090-86B4-474F3978ECC6Q38631489-FA290026-2598-42AA-B354-9C2A4A7A7B28Q38671170-96B2070D-963B-461B-AC7C-DBBEA6E8F65AQ38707012-1B5B49D9-F811-484D-8343-C68CD6140FE6Q38725930-BC157CEB-6E5D-4197-8BAD-944A8268A330Q38758065-DE909D07-93B0-4249-9EBD-9A85721A5A62Q38854599-630CB95A-C259-4538-BF1A-88B906EF1300Q38855675-4283B446-F40B-411C-8F67-647A173424DFQ38871819-84AF8A3C-B3E8-4E49-A611-F4170DB435C3Q38950445-67D567F3-59C5-43D5-8E4A-7D96E2FF9426Q39035687-A867CE09-E440-40AE-A3C4-72BA3576A2E4Q39116735-EB049FD6-9497-4A0B-B5A5-F972E1D305D7Q40417671-204B9899-BDF9-4B88-AB52-14B5A3A5AF7DQ40650299-539CAFF1-0560-4302-9267-81B767B6B323Q41991354-E560D228-A829-484F-85BF-C0CBEE105F37Q42054480-12DF5D63-CF8A-48C7-9219-BE087DACF970Q42615371-B4F84225-0653-4ECC-A2CF-53360BE03483Q42649779-9EA7B586-8E91-4870-AA05-56FD7BE098E5Q47123783-71D25D75-01EF-4B02-8AB0-555E5905DC0FQ47282721-6F767BDB-56DF-477D-ACA5-0B6281650C5EQ47324732-1690383A-418B-4A5D-820A-EB9A16A488D9Q47573527-1A3C8EFF-156C-4A1C-8CF1-C7980562C2ADQ47606195-350C4856-FF50-41C3-9374-0C8060F0BBA3Q47614940-EC748DC1-27B1-4D96-B7AA-3FE0222F3E35Q47901606-1680DC0B-8722-4086-AF00-E6BDB1FCB7BCQ48080052-A75229F1-9F67-4D89-8C9C-6905D1BBD76AQ48121156-C9093221-FBF4-44EC-A197-9F512EBFE79EQ48222690-70A29D0E-EC3D-40D9-871D-5A6C219336D5Q48301865-075A3707-2CE5-401B-9E46-F00F180D6CD5Q48515655-8C2E95B4-792B-4F40-99B3-DA211127C75D
P2860
Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Prostate cancer screening in m ...... ulation-based diagnostic study
@ast
Prostate cancer screening in m ...... ulation-based diagnostic study
@en
type
label
Prostate cancer screening in m ...... ulation-based diagnostic study
@ast
Prostate cancer screening in m ...... ulation-based diagnostic study
@en
prefLabel
Prostate cancer screening in m ...... ulation-based diagnostic study
@ast
Prostate cancer screening in m ...... ulation-based diagnostic study
@en
P2093
P50
P3181
P1433
P1476
Prostate cancer screening in m ...... ulation-based diagnostic study
@en
P2093
Fredrik Wiklund
Henrik Grönberg
James Thompson
Lars Egevad
Mark Clements
Martin Eklund
Peter Wiklund
Yvonne Brandberg
P304
P3181
P356
10.1016/S1470-2045(15)00361-7
P577
2015-11-10T00:00:00Z